Why this lesson is short
"Can I drink on this?" is one of the most asked questions in the field and one of the least answered. We went looking compound by compound for material worth publishing, and for the great majority of this library there is nothing: no trial, no sentence in a label, no study of the two together.
So this lesson is short, and it stays inside two boundaries. It reports only what a source says about a compound in this library. And it is not general drinking advice. That conversation belongs with a doctor who knows your liver, your medications and your history, not with a peptide app.
The one alcohol rule already in the library
DSIP carries the only per-compound alcohol rule we publish, and it has been on that record since it was written. Our sources place alcohol and sedatives alongside benzodiazepines as a caution, particularly in the first days, because DSIP acts on the GABA system, the same system benzodiazepines act on, and the effects are additive with any central nervous system depressant.
That rule is DSIP's. It does not transfer to the rest of the library, and pointing a general question at it would turn one specific interaction into a claim about peptides in general.
Growth hormone: two small studies, and their limits
If something in your protocol is there to raise growth hormone, one line of evidence is worth knowing. It is old, small and specific.
- Prinz and colleagues, 1980, in the Journal of Clinical Endocrinology and Metabolism: five healthy men, 0.8 g of ethanol per kilogram of bodyweight, over nine nights. Alcohol suppressed night-time plasma growth hormone by 70 to 75% on both the acute and the chronic nights, and levels returned to placebo values on the withdrawal night.
- Ekman and colleagues, 1996, in the same journal: nine healthy subjects at 0, 0.5 and 1.0 g/kg. Growth hormone rose from 0.6 micrograms per litre at 10pm to 25.0 at 1am in the control condition, and on the highest dose that rise was almost entirely blocked, at 4.5.
Read the limits with the numbers. Fourteen people in total. Healthy volunteers, not people running a protocol. Neither study involved a secretagogue. This is alcohol against the body's own night-time growth hormone, not alcohol against ipamorelin. And the doses were substantial: at the US definition of a standard drink as 14 g of pure alcohol, 0.8 g/kg is somewhere around four and a half drinks for an 80 kg adult, taken in the evening.
What that supports is one careful sentence: alcohol suppresses the same night-time growth hormone output a secretagogue is asked to raise. It is the same kind of statement this app already makes about food and the injection window, and it is as far as the evidence goes. Nobody has measured what a drink does to a dose of tesamorelin.
The GLP-1s: the studied arrow points the other way
For the incretin compounds the research that exists is not about what alcohol does to the drug. It is about what the drug does to drinking, in people being treated for alcohol use disorder.
- JAMA Psychiatry, April 2025. A phase 2 trial, 48 adults with alcohol use disorder, nine weeks, low-dose semaglutide. It reduced how much people drank in a post-treatment laboratory task, reduced drinks per drinking day and reduced weekly craving. It did not change average drinks per calendar day or the number of drinking days.
- The Lancet, May 2026. 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity, 26 weeks of once-weekly semaglutide at 2.4 mg or placebo, both on top of standard cognitive behavioural therapy. Heavy drinking days fell 41.1 percentage points from baseline on semaglutide against 26.4 on placebo, a difference of 13.7 percentage points, p=0.0015.
- A July 2026 review by the authors of that trial counts three randomised controlled trials of GLP-1 receptor agonists in alcohol use disorder to date, with registry and real-world data pointing the same way.
- For tirzepatide there is no human result yet. A phase 2 trial in adults with alcohol use disorder and overweight or obesity, around 42 participants, was recruiting as of October 2025 with primary completion estimated for August 2026.
None of that is a permission or a prohibition. These are trials in people being treated for a disorder, at a dose and in a setting with nothing to say about a Friday evening, and neither trial asked what drinking does to the medicine.
What the labels do not say
We searched the full text of the current US labels for semaglutide. In both Ozempic and Wegovy the word "alcohol" appears only in the instructions for swabbing an injection site, plus the older name for the liver condition Wegovy is approved to treat. There is no drinking guidance in either document.
An absence is not a permission. It means the question is not answered in the place most people would look first, which is worth knowing before accepting an answer from a source with far less to lose than a manufacturer under FDA review.
The BPC-157 line, read correctly
BPC-157's record describes cytoprotection, the shielding of tissue from NSAIDs, alcohol and other stressors, most pronounced in the gut. That sentence is about animal work, and about the mechanism the compound is named for.
It is not a finding that BPC-157 protects a person who drinks, and it should not be read as one. FDA's own position is that there is no information with which to assess BPC-157's pharmacokinetics in humans by any route, which is the state of the evidence underneath every claim made for it.
Everything else in the library
Nothing found, so nothing published. For the remaining compounds we hold no trial, no label statement and no study involving alcohol, and a paragraph that merely sounded plausible would be the exact failure this course spends seven modules teaching you to spot.
One adjacent flag, because it is easy to miss. PT-141 can significantly reduce the systemic exposure of oral naltrexone, which is prescribed for alcohol use disorder. If that is in your medicine cabinet, the compound page carries the detail, and it is a conversation with the prescriber managing the naltrexone rather than something to work out alone.